Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2011 / Cilt: 45 - Sayı: 2

Progressive macular hypomelanosis

Progresif maküler hipomelanozis

Pages
62–65
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper, we aimed to review the etiopathogenesis, clinical findings, histopathology, differential diagnosis and treatment options of PMH.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Progressive macular hypomelanosis (PMH) was initially described and named by Guillet in 1988.
📊
Key Findings & Data:The histopathologic findings in PMH are usually non-specific, but a common feature is the decreased melanin content in the hypopigmented macules compared to the normal skin.
💡
Conclusion & Impact:In this paper, we aimed to review the etiopathogenesis, clinical findings, histopathology, differential diagnosis and treatment options of PMH.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Progressive macular hypomelanosis (PMH) was initially described and named by Guillet in 1988. PMH is characterized by asymptomatic, ill-defined, nummular, non-scaly, hypopigmented macules, localized predominantly on the trunk. PMH is mostly seen in adolescents and young females. The etiopathogenesis of PMH is still unknown. The red follicular fluorescence becomes visible in the hypopigmented macules under Wood’s lamp but is absent in normal adjacent skin. The histopathologic findings in PMH are usually non-specific, but a common feature is the decreased melanin content in the hypopigmented macules compared to the normal skin. No effective therapy is currently known. Phototherapy was found to be effective for the control of PMH; however, it does not prevent recurrence of the disease. In this paper, we aimed to review the etiopathogenesis, clinical findings, histopathology, differential diagnosis and treatment options of PMH.

Özet

Progresif maküler hipomelanozis (PMH) ilk olarak 1988 yılında Guillet tarafından tanımlanmıştır. PMH sıklıkla gövdeyi tutan, asemptomatik, zor fark edilen, numuler, skuamsız, hipopigmente makûllerle karakterizedir. PMH çoğunlukla adölesan ve genç kadınlarda görülür. Etyopatogenezi hala bilinmemektedir. Wood lambası altında hipopigmente makûllerde kırmızı foliküler flo-rasan görünürken komşu normal deride florasan gözlenmez. PMH'nin histopatolojik bulguları genellikle non-spesifiktir, ancak hipopigmente makûllerin melanin içeriğinin normal deriye göre azalmış olması sık görülen bir bulgudur. Etkili bir tedavi halen bilinmemektedir. Ancak fototerapi PMH'yi kontrol altına almada etkili bulunmuş olmasına karşın hastalığın rekürrensini önlememektedir. Biz bu makalede PMH'nin etyopatogenezi, klinik bulguları, histopatolojisi, ayırıcı tanısı ve tedavi seçeneklerini derlemeyi amaçladık. (Türkderm 2011; 45: 62-5)

🔖

Cite This Article

AYKOL, C., MEVLİTOĞLU, İ. (2022). Progressive macular hypomelanosis. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 45 - Sayı: 2, 62–65. https://ajindex.com/articles/621977

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Guillet G, Helenon R, Gauthier Y, Surleve-Bazeille JE, Plantin P, Sassolas B: Progressive macular hypomelanosis of the trunk: primary acquired hypopigmentation. J Cutan Pathol 1988;15:286-9
  2. Relyveld GN, Menke HE, Westerhof W: Progressive macular hypomelanosis: an overview. Am J Clin Dermatol 2007;8:13-9
  3. Wu XG, Xu AE, Song XZ, Zheng JH, Wang P, Shen H: Clinical, pathologic, and ultrastructural studies of progressive macular hypomelanosis. Int J Dermatol 2010;49:1127-32
  4. Borelli D: [Cutis "trunci variata." A new genetic dermatosis]. Med Cutan Ibero Lat Am 1987;15:317-9
  5. Fitzpatrick TB. In: Sober AJ, Fitzpatrick TB, editors: Yearbook of dermatology. St Louis (MO): Mosby-Year Book, 1996:416-7
  6. Hwang SW, Hong SK, Kim SH et al: Progressive macular hypomelanosis in korean patients: a clinicopathologic study. Ann Dermatol 2009;21:261-7
  7. Westerhof W, Relyveld GN, Kingswijk MM, de Man P, Menke HE: Propionibacterium acnes and the pathogenesis of progressive macular hypomelanosis. Arch Dermatol 2004;140:210-4
  8. Relyveld GN, Westerhof W, Woudenberg J et al: Progressive macular hypomelanosis is associated with a putative Propionibacterium species. J Invest Dermatol 2010;130:1182-4
  9. Neynaber S, Kirschner C, Kamann S, Plewig G, Flaig MJ: Progressive macular hypomelanosis: a rarely diagnosed hypopigmentation in Caucasians. Dermatol Res Pract 2009;2009:607682
  10. Erpolat S, Gorpelioglu C, Sarifakioglu E: A case of progressive macular hypomelanosis treated with 1% topical clindamycin lotion and narrow-band ultraviolet B. Photodermatol Photoimmunol Photomed 2010;26:277-8
  11. Kumarasinghe SP, Tan SH, Thng S, Thamboo TP, Liang S, Lee YS: Progressive macular hypomelanosis in Singapore: a clinico-pathological study. Int J Dermatol 2006;45:737-42
  12. Duarte I, Nina BI, Gordiano MC, Buense R, Lazzarini R: Progressive macular hypomelanosis: an epidemiological study and therapeutic response to phototherapy. An Bras Dermatol 2010;85:621-4
  13. Relyveld GN, Dingemans KP, Menke HE, Bos JD, Westerhof W: Ultrastructural findings in progressive macular hypomelanosis indicate decreased melanin production. J Eur Acad Dermatol Venereol 2008;22:568-74
  14. Relyveld GN, Kingswijk MM, Reitsma JB, Menke HE, Bos JD, Westerhof W: Benzoyl peroxide/clindamycin/ultraviolet A is more effective than fluticasone/ultraviolet A in progressive macular hypomelanosis: a randomized study. J Am Acad Dermatol 2006;55:836-43
  15. Chung YL, Goo B, Chung WS, Lee GS, Hann SK: A case of